Multaq Sucks

[anonymous]

How do they expect anyone to sell this piece of sh*t overpriced drug Multaq? They are becoming desperate now pushing VERNE. That is what reps want…to record a video of themselves appearing desperate and awkward to send out to highly regarded cardiologists.

 

[anonymous]

How do they expect anyone to sell this piece of sh*t overpriced drug Multaq? They are becoming desperate now pushing VERNE. That is what reps want…to record a video of themselves appearing desperate and awkward to send out to highly regarded cardiologists.

Reps at launch meeting thought drug should be pulled from market

 

[anonymous]

I mean cardiologists straight up cringe at the mention of the drug.

 

[anonymous]

I mean cardiologists straight up cringe at the mention of the drug.

Did sanofi pull their GLP-1? And they spent 12 billion on not bringing out Accomplia, a weight loss agent.
They just burn stockholder $$$ and the stock stays in same range.

 

[anonymous]

I was not aware of Sanofi having a GLP-1 prior to a week or so ago. I came across talk of it.

They had forked over a ton of money upfront back in like 2015 to partner with Hanmi Pharma then pulled out of the deal in 2019 when new CEO joined and cut diabetes and cardio R&D.

The GLP-1 never made it to market. Not sure what the status of it is but Sanofi no longer a partner for it.

 

[anonymous]

I was not aware of Sanofi having a GLP-1 prior to a week or so ago. I came across talk of it.

They had forked over a ton of money upfront back in like 2015 to partner with Hanmi Pharma then pulled out of the deal in 2019 when new CEO joined and cut diabetes and cardio R&D.

The GLP-1 never made it to market. Not sure what the status of it is but Sanofi no longer a partner for it.

This just screams typical sanofi. Their pipeline isn't looking as good as they hoped. So many things are failing in the later stages. There's barely anything left. Very few oncology, no more MS, rheum has a few dozen, rare/rare blood don't have a lot going on, and then dupi. Which will lose its patent in what, 5 years?

 

[anonymous]

And Multaq loses its patent in 2029. Now they want to stick Toujeo reps with Tzield. Thats another winner.

 

[anonymous]

I was not aware of Sanofi having a GLP-1 prior to a week or so ago. I came across talk of it.

They had forked over a ton of money upfront back in like 2015 to partner with Hanmi Pharma then pulled out of the deal in 2019 when new CEO joined and cut diabetes and cardio R&D.

The GLP-1 never made it to market. Not sure what the status of it is but Sanofi no longer a partner for it.

 

[anonymous]

Google "adlyxin" Sanofi's discontinued GLP-1.

 

[anonymous]

Downsized 5 years ago, glad to see all the cost cutting measures that the CEO has done has worked wonders on the stock price $48 , lower now than when I was downsized a job well done.
Amazing how the French continue to stick with somebody that burns and slashes and accounted for no shareholder value.

 

[anonymous]

Google "adlyxin" Sanofi's discontinued GLP-1.

The Sanofi idiots couldn’t figure out how to generate demand even if they were trying to sell dollar bills for 99 cents.

 

[anonymous]

The Sanofi idiots couldn’t figure out how to generate demand even if they were trying to sell dollar bills for 99 cents.

The bills would be on backorder and sanofi CEO would lay off cashiers to save $$$

 

[anonymous]

I was not aware of Sanofi having a GLP-1 prior to a week or so ago. I came across talk of it.

They had forked over a ton of money upfront back in like 2015 to partner with Hanmi Pharma then pulled out of the deal in 2019 when new CEO joined and cut diabetes and cardio R&D.

The GLP-1 never made it to market. Not sure what the status of it is but Sanofi no longer a partner for it.

https://professionals.optumrx.com/c...thdrawls/drugwithdrawal_adlyxin_2023-0117.pdf

 

[anonymous]

Did sanofi pull their GLP-1? And they spent 12 billion on not bringing out Accomplia, a weight loss agent.
They just burn stockholder $$$ and the stock stays in same range.

Just to be clear Accomplia was turned down 14-0 by the FDA vote. They discussed spent a great deal of money and mostly the motivation to buy Aventis to get the rights to Accomplia. Typical French arrogance followed as they thought they could push this through without any FDA push back. Sanofi was never.the same especially when they hired 5000 reps to sell Accomplia to then lay them off. Only at Sanofi!

 

[anonymous]

Downsized 5 years ago, glad to see all the cost cutting measures that the CEO has done has worked wonders on the stock price $48 , lower now than when I was downsized a job well done.
Amazing how the French continue to stick with somebody that burns and slashes and accounted for no shareholder value.

Hudson has done nothing. All the massive layoffs and shutting down cardiovascular division which built the company was the kiss of death. It also started with that asshole Viehbacher as he screwed up Diabetes division and failed to invest in any cardiovascular or diabetes pipeline and virtually drove the bus over the patent cliff. Plavix, Lovenox and Lantus paid all the bills back then. After a few pharma rejects were circulated through that Limey Hudson arrived. Thinking he could drive the stock price up by closing divisions down backfired. The stock has performed poorly since 2020. Sanofi always was and will continue to be the most incompetent company in pharma. How Hudson is still collecting a check is a miracle. Watching his arrogance in testifying in front of the senate only showcased how out of touch he is.